Literature DB >> 2861769

Malignant insulinoma: effects of a somatostatin analog (compound 201-995) on serum glucose, growth, and gastro-entero-pancreatic hormones.

K Osei, T M O'Dorisio.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2861769     DOI: 10.7326/0003-4819-103-2-223

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


× No keyword cloud information.
  8 in total

1.  Preventive effects of octreotide (SMS 201-995) on diabetic ketogenesis during insulin withdrawal.

Authors:  P Diem; R P Robertson
Journal:  Br J Clin Pharmacol       Date:  1991-11       Impact factor: 4.335

Review 2.  Somatostatin.

Authors:  S R Bloom; J M Polak
Journal:  Br Med J (Clin Res Ed)       Date:  1987-08-01

Review 3.  Somatostatin and analogues in the treatment of cancer. A review.

Authors:  B M Evers; D Parekh; C M Townsend; J C Thompson
Journal:  Ann Surg       Date:  1991-03       Impact factor: 12.969

4.  Control of plasma glucose with somatostatin analogue (SMS 201-995) during surgical removal of insulinomas.

Authors:  C Utas; F Kelestimur; A Boyaci; A Saglam
Journal:  Postgrad Med J       Date:  1993-12       Impact factor: 2.401

Review 5.  Biology of pancreatic cancer.

Authors:  G J Poston; J Gillespie; P J Guillou
Journal:  Gut       Date:  1991-07       Impact factor: 23.059

Review 6.  Octreotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion.

Authors:  P E Battershill; S P Clissold
Journal:  Drugs       Date:  1989-11       Impact factor: 9.546

Review 7.  Somatostatin analogues for the treatment of hyperinsulinaemic hypoglycaemia.

Authors:  Basma Haris; Saras Saraswathi; Khalid Hussain
Journal:  Ther Adv Endocrinol Metab       Date:  2020-12-02       Impact factor: 3.565

8.  Somatostatin binding in normal and malignant human gastrointestinal mucosa.

Authors:  G V Miller; S M Farmery; L F Woodhouse; J N Primrose
Journal:  Br J Cancer       Date:  1992-08       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.